<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The dramatic increase in the incidence and poor overall survival rates of esophageal/gastroesophageal junction <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> underscore the necessity to discover molecular markers that can be used for risk assessment, early diagnosis, and targeted therapeutic intervention </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) is proposed to represent a precursor of esophageal/gastroesophageal junction <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>BE progression to <z:e sem="disease" ids="C0677898" disease_type="Neoplastic Process" abbrv="">invasive cancer</z:e> is defined by a <z:mpath ids='MPATH_160'>metaplasia</z:mpath>-<z:mpath ids='MPATH_589'>dysplasia</z:mpath>-<z:mp ids='MP_0002038'>carcinoma</z:mp> progression characterized by an increasing accumulation of genetic changes associated with alterations in molecular gatekeepers of cell circuitries and tissue homeostasis </plain></SENT>
<SENT sid="3" pm="."><plain>Using a combination of in situ tissue-based and high-throughput analyses, we investigated alterations of cell-cycle regulators and <z:mp ids='MP_0001845'>inflammation</z:mp>-associated molecular effectors </plain></SENT>
<SENT sid="4" pm="."><plain>Our data suggest a potential synergistic effect of these alterations for the BE progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, and underscore the potential use of these markers: (1) in molecular panels assessing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in BE patients; and (2) as potential therapeutic targets for chemopreventive interventions and to enhance response to anti-neoplastic therapies </plain></SENT>
</text></document>